Researcher Profile

F. Dalenc

Publications

1,082

Citations

Co-Authors

Active Years

Publications

Open Access Journal Article Annals of Oncology Nov 01, 2025

Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer

A. Mamann · Y. Pradat · F.C. Bidard · S. Delaloge +21 more

10.1016/j.annonc.2025.06.015 5 citations

Open Access Journal Article ESMO Open May 01, 2024

198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009

A. Llombart Cussac · H.S. Rugo · M.E. Robson · S-A. Im +16 more

10.1016/j.esmoop.2024.103220 4 citations

Open Access Journal Article Annals of Oncology Sep 01, 2021

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

A. Bardia · S.M. Tolaney · K. Punie · D. Loirat +23 more

10.1016/j.annonc.2021.06.002 254 citations

Open Access Journal Article Annals of Oncology Aug 01, 2021

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

D. Miles · J. Gligorov · F. André · D. Cameron +155 more

10.1016/j.annonc.2021.05.801 578 citations

Open Access Journal Article Annals of Oncology May 01, 2016

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

H. Bonnefoi · T. Grellety · O. Tredan · M. Saghatchian +19 more

10.1093/annonc/mdw067 241 citations

Publication Timeline

2025

2024

2021

2016

Frequent Co-Authors

2×

2×

2×

2×

2×

2×

2×

2×

2×

2×